EMA Authorised: Aquipta (atogepant) — AbbVie Deutschland GmbH & Co. KG

View source ↗

Summary

Aquipta (atogepant) has been authorised by the EMA for migraine disorders, under AbbVie Deutschland GmbH & Co. KG.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine Disorders

Drugs mentioned

• Aquipta (atogepant)

Snippet

Status: Authorised. Therapeutic area: Migraine Disorders. MAH: AbbVie Deutschland GmbH & Co. KG. Decision date: 29/05/2026